While GLP-1 and GLP-1/GIP medications are generally considered cost-effective for treating obesity in targeted populations [65,66,67], alternative strategiessuch as expanding bariatric surgery access, enhancing lifestyle intervention programmes, pharmaceutical management of cardiometabolic comorbidities, or population-level policiesshould also be considered
IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma
PMID: 30554025 Neuro Oncol A disintegrin and metalloproteinase 22 activates integrin 1 through its disintegrin domain to promote the progression of pituitary adenoma
Some women exploring microdosing GLP-1 in perimenopause or menopause report improvements in metabolic weight gain, hot flashes, brain fog, and energy fluctuations
Explained simply and clearly in this short video